If a patient with MSI-H endometrial cancer slowly progresses on single-agent pembrolizumab, would you add lenvatinib?  

This is an important question without a defined answer at this time. In a prior phase 2 trial examining cabozantinib + nivolumab in endometrial cancer, a small exploratory cohort of patients treated with prior IO was included. Of 20 patients who received prior IO, six patients responded and eight ha...